Imbruvica(Ibrutinib)
ABBV
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by AbbVie Inc.
$2.27B
Medicare cost, 2024
$2.27B
Medicare cost, 2024
Medicare drug plans spent $2.3 billion on Imbruvica (ibrutinib) in 2024, for 146,351 prescriptions and refills filled by 15,343 patients. It ranks 20th among all drugs by Medicare drug plan spending. At about $15,478 per prescription it is a high-cost drug. California accounts for the most spending ($205.8 million, 9% of the total).
Medicare cost, 2024
$2.27B
-4.4% from 2023
Prescriptions
146K
$15,477.88 per claim
Patients
15K
8,828 prescribers
Total spending, 2024
$2.27B
$147,628.95 per patient
Questions and answers
How much does Medicare spend on Imbruvica?
Medicare prescription drug plans paid $2.27B for Imbruvica in 2024, for 146,351 prescriptions and refills to 15,343 patients (down 4.4% from 2023). The average cost per claim was $15,477.88.
Which state spends the most on Imbruvica?
California had the highest Medicare cost for Imbruvica in 2024: $205.8M for 13,081 claims, followed by New York ($181.0M).
Who prescribes Imbruvica the most?
Josie Montegaard, nurse practitioner in Boston, MA, had the highest Medicare cost for Imbruvica in 2024: 231 claims costing $3.6M.
Who makes Imbruvica?
Imbruvica is made by AbbVie Inc. (ABBV), listed in the Medicare spending data as Pharmacyclics,.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Imbruvica was $2.27B in 2024, after a high of $3.15B in 2021.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Imbruvica, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Josie Montegaard Boston, MA | Nurse Practitioner | 231 | 25 | $3.6M |
| Sami N Malek Ann Arbor, MI | Hematology | 163 | 18 | $2.8M |
| Erin M Pettijohn Grand Rapids, MI | Hematology-Oncology | 183 | 18 | $2.8M |
| Michael P Carroll Sacramento, CA | Hematology-Oncology | 160 | 17 | $2.7M |
| Samer E Bibawi Richardson, TX | Hematology-Oncology | 147 | 15 | $2.5M |
| Thomas J Kipps La Jolla, CA | Hematology-Oncology | 156 | 16 | $2.5M |
| Rajeev Kulkarni Troy, OH | Hematology-Oncology | 154 | 15 | $2.4M |
| Jeffrey H Margolis Madison Heights, MI | Hematology-Oncology | 144 | 13 | $2.3M |
| Catherine A Flynn Boston, MA | Nurse Practitioner | 153 | 22 | $2.3M |
| Eric D Batts Holland, MI | Hematology-Oncology | 161 | 14 | $2.3M |
| Jose M Tongol Albany, GA | Hematology-Oncology | 139 | 14 | $2.3M |
| Antoine E Chahine Canfield, OH | Medical Oncology | 140 | 12 | $2.2M |
| Michael Y Choi San Diego, CA | Hematology-Oncology | 147 | 16 | $2.2M |
| Sanjaykumar J Hapani Edmond, OK | Medical Oncology | 139 | 16 | $2.2M |
| Tania Orzol Rochester, NY | Nurse Practitioner | 119 | 19 | $2.2M |
| Nicholas O Iannotti Port St Lucie, FL | Hematology-Oncology | 140 | 14 | $2.1M |
| Matthew E Adess Highland Park, IL | Medical Oncology | 135 | 13 | $2.1M |
| Mark E Dailey Hartford, CT | Medical Oncology | 111 | Under 11 | $2.1M |
| James L Rubenstein San Francisco, CA | Medical Oncology | 79 | 11 | $2.1M |
| Mohammad I Khan Louisville, KY | Hematology-Oncology | 127 | 11 | $2.0M |
| Pamela R Sinclair Rock Hill, SC | Medical Oncology | 123 | 11 | $2.0M |
| Joseph D Te St George, UT | Hematology-Oncology | 123 | 11 | $2.0M |
| Robert M Zielinski Williamsville, NY | Hematology | 124 | 13 | $1.9M |
| Hassan I Tahsildar Green Bay, WI | Medical Oncology | 119 | 13 | $1.9M |
| Jorge Castillo Boston, MA | Hematology-Oncology | 134 | 23 | $1.9M |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 10,064 | 195,587 | 22,193 | $2.85B |
| 2023 | 9,115 | 151,924 | 17,085 | $2.37B |
| 2024 | 8,828 | 146,351 | 15,343 | $2.27B |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Pharmacyclics, | 146,416 | $2.27B |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 7
- RxNorm concept IDs
- 1442986, 1442992, 1994360, 1994362, 2000017
- Application numbers
- NDA205552, NDA210563, NDA217003
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 80,997 side-effect reports named ibrutinib, the active ingredient of Imbruvica (reports from 2012 on). 63,021 of them (77.8%) were serious, 13,832 named a death and 26,987 named a hospital stay. The reactions named most often were death, off label use and fatigue. 31,944 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
80,997
3,593 in 2025 (-19.1% from 2024)
Serious
77.8%
63,021 reports
Deaths named
13,832
17.1% of reports
Hospital stays
26,987
33.3% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Imbruvica?
80,997 reports from 2012 through September 2026 named ibrutinib, the active ingredient of Imbruvica. 63,021 of them (77.8%) were serious, 13,832 named a death and 26,987 named a hospital stay.
What are the most reported side effects of Imbruvica?
8,652 reports named death, the reaction named most often, followed by off label use (6,069) and fatigue (4,780). In the last 5 years the reaction named most often was death (3,877 reports). A report can name several reactions.
How many side-effect reports named Imbruvica in 2025?
3,593 reports were received in 2025 (-19.1% from 2024). 2026 so far: 2,158 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Imbruvica caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Imbruvica caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
ABBV·ABBV drug pipeline - Drug approvals (3 approvals on file for ibrutinib) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (ibrutinib) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.